Immunosuppressive peptides having glycosylation inhibiting factor activity are provided. The peptides include the following sequence and its homologs: ##STR1##

The invention relates to pharmaceutical compositions comprising at least one Vitamin D derivative and a method of using the pharmaceutical compositions in suppressing immune responses.

The present invention provides certain novel .omega.-(alkoxycarbonyl)alkyl esters of dithiocarbanilic acid and certain aryl-substituted acids related thereto. These compounds are disclosed as immunoregulatory agents, useful in the treatment of organ transplant reject phenomena and autoimmune diseases such as arthritis. Additionally, there is described by the present invention the immunoregulatory use of .omega.-carboxyalkyl and .omega.-(alkoxycarbonyl)alkyl esters of dithiocarbanilic acid and ce...

A pharmaceutical composition containing a non-specific (NS) suppressor cell inducing compound and cyclosporin A and a pharmaceutically acceptable carrier or diluent, and method of inducing an immunosuppressive effect in a mammal, including a hyman, in need thereof which comprises administering an effective dose of a non-specific suppressor cell inducing compound and cyclosporin A to such mammal.

An immunosuppressive agent comprising, as an effective ingredient, at least one compound selected from the group consisting of compounds represented by general formula (1) below and pharmaceutically acceptable salts thereof: ##STR1## wherein R.sub.101 represents an acyl residue of a higher fatty acid, and R.sub.102 represents a hydrogen atom or acyl residue of a higher fatty acid.

Immunosuppressive polypeptide (ISP) in substantially pure form is disclosed. Monoclonal antibodies to ISP are also described. Treatment of immune dysfunctions with ISP in substantially pure form and anti-ISP antibodies is also disclosed.

The present invention provides an immunosuppressive agent containing an effective amount of one or more of the macrolide antibiotics of the formula (I): ##STR1## (wherein each of R.sub.1, R.sub.2, R.sub.3 and R.sub.4 is a methyl or ethyl group). The immunisuppressive agent has excellent immuno-suppressive activity and can be employed as an agent for suppressing rejection occurring after organ transplantation and as an agent for treating autoimmune diseases.

The present invention is directed to certain 2-aryl-1H-perimidines as immunosuppressive agents.

An immunosuppressive agent which is very effective for treating autoimmune disease, inflammatory reaction, fibrosis or dysfunction caused by autoimmune disease and related disease thereof with tissue injury or infection, rejection of transplantation, graft versus host disease by bone marrow (hematopoietic stem cell) transplantation, or allergic disease, by selectively inhibiting the activated T cells, is provided.

A compound with immunosuppressive properties having formula (I), in which R.sup.1 represents a heterocyclic ring system, a combined heterocyclic ring system and homocyclic ring system, or an ethoxycarbonylmethyl group. R.sup.2 and R.sup.3 represent hydrogen or lower alkyl groups.